The performance ceiling for non-invasive Brain-Computer Interfaces (BCIs) is rising dramatically, not from better sensors, but from advanced AI. New models can extract high-fidelity signals from noisy data collected outside the skull, potentially making surgical implants like Neuralink unnecessary for sophisticated use cases.

The endgame for CZI's work is hyper-personalized, "N of one" medicine. Instead of the current empirical approach (e.g., trying different antidepressants for months), AI models will simulate an individual's unique biology to predict which specific therapy will work, eliminating guesswork and patient suffering.

Broad diagnostic categories like 'diabetes' or 'insomnia' likely encompass several distinct underlying conditions. Continuous data streams from wearables and CGMs can help researchers identify these subtypes, paving the way for more personalized treatments.

Challenging Neuralink's implant-based BCI, Merge Labs is creating a new paradigm using molecules, proteins, and ultrasound. This less invasive approach aims for higher bandwidth by interfacing with millions of neurons, fundamentally rethinking how to connect brains to machines.

Paradromics' founder notes that while the FDA is collaborative, the slower, understaffed CMS, which determines reimbursement for Medicare/Medicaid patients, is the primary bottleneck. Gaining its approval is critical for market access, as private insurers often follow its lead.

Paradromics uses LLMs to decode brain signals for speech, much like how speech-to-text cleans up audio. This allows for faster, more accurate "thought-to-text" by predicting what a user intends to say, even with imperfect neural data, and correcting errors in real-time.

A Quantitative EEG (QEEG) or "brain map" analyzes brainwave patterns to identify cognitive struggles and even sleep quality. Practitioners can often describe a person's core challenges with surprising accuracy, providing objective data before any subjective report is given.

Paradromics measures its technological advancement by the number of neurons it can record from, directly impacting the BCI's data rate. This "neurons per device" metric serves as an industry benchmark, similar to how transistor density drove progress in semiconductors.

The company first targets patients with disabilities, a clear medical need. By restoring functions like speech, they create platforms for enhanced abilities (e.g., prompting AI with thoughts), paving the way for a wider consumer market where the risk-benefit calculation shifts over time.